High expression of long noncoding RNA LUCAT1 correlates with a poor clinical outcome in solid tumors: A systematic review and meta-analysis

2020 ◽  
Vol 216 (9) ◽  
pp. 153047
Author(s):  
Peng Lv ◽  
Tao Ye ◽  
Xiaoqi Yang ◽  
Haoran Liu ◽  
Zhangqun Ye
2019 ◽  
Vol 10 (11) ◽  
pp. 2386-2396 ◽  
Author(s):  
Yu Zhou ◽  
Rui Wang ◽  
Tian Xu ◽  
Ping Xie ◽  
Yun Zhang ◽  
...  

Oncotarget ◽  
2017 ◽  
Vol 8 (59) ◽  
pp. 100490-100498 ◽  
Author(s):  
Tian Lan ◽  
Xiong Lan ◽  
Guangcai Li ◽  
Zhen Zheng ◽  
Minghua Zhang ◽  
...  

2018 ◽  
Vol 49 (1) ◽  
pp. 134-143 ◽  
Author(s):  
Cheng-Peng Yu ◽  
Shu-Fang Fu ◽  
Xuan Chen ◽  
Jing Ye ◽  
Yuan Ye ◽  
...  

Background/Aims: Indoleamine 2,3-dioxygenase 1 (IDO1) is a heme-containing enzyme catalyzing the initial and rate-limiting steps in the kynurenine pathway, which converts tryptophan into kynurenine. Upregulation of IDO1 decreases tryptophan levels and increases the accumulation of kynurenine and its metabolites. These metabolites can affect the proliferation of T cells. Increasing evidence has shown that IDO1 is highly expressed in various cancer types and associated with poor prognosis of cancer patients. However, the results were inconsistent. Methods: We searched the Web of Science, PubMed, Embase and Cochrane library databases to identify studies evaluating the prognostic value of IDO1 in cancer patients. Pooled hazard ratios (HRs) or odds ratios (ORs) with 95% confidence intervals (CIs) were calculated by using fixed-effects/random-effects models. Results: This systematic review and meta-analysis included 2706 patients from 24 articles. The results indicated a shorter overall survival in patients with high expression of IDO1 (hazard ratio [HR] = 2.03, 95% confidence interval [CI]: 1.56-2.63). Furthermore, disease-free survival was worse in patients with high expression of IDO1 (HR = 2.47, 95% CI: 1.46-4.20). Additionally, the pooled odds ratios (ORs) showed that increased IDO1 was significantly associated with tumor differentiation (OR = 1.81, 95% CI: 1.05-3.12), distant metastasis (OR = 1.45, 95% CI: 1.02-2.06), and poor clinical stage (OR = 1.89, 95% CI: 1.13-3.17). However, no significant correlation was observed of increased IDO1 expression with age, sex, lymph node metastasis, and tumor size. Conclusion: High expression of IDO1 is associated with poor clinical outcomes. IDO1 could serve as a biomarker of prognosis and a potential predictive factor of clinicopathology in various cancers. Further studies should be performed to verify the clinical utility of IDO1 in human solid tumors.


2017 ◽  
Vol 8 ◽  
Author(s):  
Qunjun Gao ◽  
Haibiao Xie ◽  
Hengji Zhan ◽  
Jianfa Li ◽  
Yuchen Liu ◽  
...  

2016 ◽  
Vol Volume 9 ◽  
pp. 4247-4254 ◽  
Author(s):  
Hong-liang Luo ◽  
Qi-zhen Xue ◽  
Pei-qian Zhu ◽  
Yi Zhang ◽  
Fang-teng Liu ◽  
...  

2020 ◽  
Vol 75 ◽  
pp. S4-S5
Author(s):  
Fuat Aksoy ◽  
Halit Ziya Dundar ◽  
Secil Ak Aksoy ◽  
Berrin Tunca ◽  
Pinar Tasar ◽  
...  

2017 ◽  
Vol 16 (6) ◽  
pp. 727-735
Author(s):  
Jun Zhao ◽  
Yali Qi ◽  
Jiahao Hu ◽  
Wenwen Dai ◽  
Yifei Chen

Sign in / Sign up

Export Citation Format

Share Document